Cylooxygenase-dependent Formation of the Isoprostane, 8-Epi Prostaglandin F2α(*)

Isoprostanes are a family of prostaglandin (PG) isomers formed in an enzyme-independent manner. They circulate in plasma and are excreted in urine. One of them, 8-epi PGF2αis a vasoconstrictor and mitogen, effects which are prevented by thromboxane antagonists. Given that 8-epi PGF2α may be formed by cyclooxygenase (COX) (Corey, E. J., Shih, C., Shig, N-Y., and Shimoji, K. (1984) Tetrahedron Letts. 44, 5013-5016; Hecker, M., Ullrich, V., Fischer, C., and Meese, C. O. (1987) Eur J. Biochem. 169, 113-123) and that this might confound its use as an index of free radical generation, we sought to characterize the mechanism of its formation by human platelets. Activation of platelets by threshold concentrations of collagen, thrombin, and arachidonic acid resulted in formation of 8-epi PGF2αcoincident with that of the COX product, thromboxane, and the 12 lipoxygenase product, 12-hydroxyeicosatetraenoic acid, as detected by selected ion monitoring assays using gas chromatography-mass spectrometry. The effect appeared selective for 8-epi PGF2α among the F2isoprostanes. Pretreatment of platelets with aspirin or indomethacin abolished 8-epi PGF2α formation. COX-independent activation of platelets by high doses of collagen or thrombin, by the phorbol ester, phorbol 12-myristate 13-acetate, or the prostaglandin endoperoxide analog, U 46619 was not associated with 8-epi PGF2α formation. Confirmation of the nature of the material formed by platelet COX as 8-epi PGF2α included its cochromatography over three highly resolving high performance liquid chromatography systems, identification by electron impact mass spectrometry, and its formation by partially purified COX. Inhibition of platelet thromboxane formation was associated with augmented 8-epi PGF2α formation.A major component of 8-epi PGF2α formed in serum by healthy volunteers was shown to be sensitive to inhibition by aspirin ex vivo. In addition to its generation by free radical catalyzed mechanisms, 8-epi PGF2α may be formed as a PG by human platelets. Given that activation of platelet COX characterizes many of the human syndromes which are putatively associated with free radical generation, assessment of the contribution of this pathway is relevant to the use of 8-epi PGF2α as an index of lipid peroxidation in vivo.

[1]  G. FitzGerald,et al.  Cyclooxygenase‐Dependent Formation of the Isoprostane 8‐EPI Prostaglandin F2α a , 1994, The Journal of biological chemistry.

[2]  K. Kent,et al.  Additions and Corrections to Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor. , 1994, The Journal of Biological Chemistry.

[3]  G. Lutty,et al.  Determination of the mechanism of free radical generation in human aortic endothelial cells exposed to anoxia and reoxygenation. , 1994, The Journal of biological chemistry.

[4]  P. Halushka,et al.  Antiaggregatory activity of 8-epi-prostaglandin F2 alpha and other F-series prostanoids and their binding to thromboxane A2/prostaglandin H2 receptors in human platelets. , 1994, The Journal of pharmacology and experimental therapeutics.

[5]  E. Änggård,et al.  Formation of F2‐isoprostanes during aortic endothelial cell‐mediated oxidation of low density lipoprotein , 1994, FEBS letters.

[6]  A. Dabbagh,et al.  The effect of iron overload on rat plasma and liver oxidant status in vivo. , 1994, The Biochemical journal.

[7]  E. Anggard,et al.  Formation of PGF2-isoprostanes during the oxidative modification of low density lipoprotein. , 1994, Biochemical and biophysical research communications.

[8]  G. FitzGerald,et al.  Cellular Activation of Thromboxane Receptors a , 1994, Annals of the New York Academy of Sciences.

[9]  J. Morrow,et al.  Formation of non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in plasma and low density lipoprotein exposed to oxidative stress in vitro. , 1994, The Journal of clinical investigation.

[10]  J. Morrow,et al.  Free radical-induced generation of isoprostanes in vivo. Evidence for the formation of D-ring and E-ring isoprostanes. , 1994, The Journal of biological chemistry.

[11]  J. Morrow,et al.  Evidence that the F2-isoprostane, 8-epi-prostaglandin F2α, is formed in vivo , 1994 .

[12]  S. Narumiya,et al.  Characterization and chromosomal mapping of the human thromboxane A2 receptor gene. , 1993, The Journal of biological chemistry.

[13]  J. Morrow,et al.  Collision-induced dissociation of F2-isoprostane-containing phospholipids. , 1993, Journal of lipid research.

[14]  J. Morrow,et al.  Evidence for the existence of F2-isoprostane receptors on rat vascular smooth muscle cells. , 1993, The American journal of physiology.

[15]  J. Manson,et al.  Vitamin E consumption and the risk of coronary disease in women. , 1993, The New England journal of medicine.

[16]  E. Rimm,et al.  Vitamin E consumption and the risk of coronary heart disease in men. , 1993, The New England journal of medicine.

[17]  J. Morrow,et al.  Formation of novel non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in carbon tetrachloride hepatotoxicity. An animal model of lipid peroxidation. , 1992, The Journal of clinical investigation.

[18]  J. Morrow,et al.  Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[19]  A. L. Goldin,et al.  Protein kinase A phosphorylation enhances sodium channel currents in Xenopus oocytes. , 1992, The American journal of physiology.

[20]  J. Morrow,et al.  The F2-isoprostane, 8-epi-prostaglandin F2 alpha, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist. , 1992, Prostaglandins.

[21]  J. Morrow,et al.  Glomerular actions of a free radical-generated novel prostaglandin, 8-epi-prostaglandin F2 alpha, in the rat. Evidence for interaction with thromboxane A2 receptors. , 1992, The Journal of clinical investigation.

[22]  G. FitzGerald,et al.  Heterogeneity of prostaglandin H2/thromboxane A2 receptors: distinct subtypes mediate vascular smooth muscle contraction and platelet aggregation. , 1991, The Journal of pharmacology and experimental therapeutics.

[23]  S. Nakanishi,et al.  Cloning and expression of cDNA for a human thromboxane A2 receptor , 1991, Nature.

[24]  J. Morrow,et al.  A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[25]  G. FitzGerald,et al.  The response to thromboxane A2 analogues in human platelets. Discrimination of two binding sites linked to distinct effector systems. , 1990, The Journal of biological chemistry.

[26]  J. Morrow,et al.  Noncyclooxygenase oxidative formation of a series of novel prostaglandins: analytical ramifications for measurement of eicosanoids. , 1990, Analytical biochemistry.

[27]  G. FitzGerald,et al.  Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. , 1988, Circulation.

[28]  M. Hecker,et al.  Identification of novel arachidonic acid metabolites formed by prostaglandin H synthase. , 1987, European journal of biochemistry.

[29]  J. Murray,et al.  Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. , 1987, Circulation.

[30]  G. FitzGerald,et al.  The biochemical pharmacology of thromboxane synthase inhibition in man. , 1985, Circulation.

[31]  E. Corey,et al.  Preferential formation of 8-epi-prostaglandin f2α via the corresponding endoperoxide by a biomimetic cyclization , 1984 .

[32]  R. A. Johnson,et al.  Inhibition of platelet thromboxane A2 synthase activity by sodium 5-(3'-pyridinylmethyl)benzofuran-2-carboxylate. , 1983, Prostaglandins.

[33]  G. FitzGerald,et al.  Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. , 1983, The Journal of clinical investigation.

[34]  Shozo Yamamoto,et al.  Inhibiton of platelet aggregation by 1-alkylimidazole derivatives, thromboxane a synthethase inhibitors , 1981 .

[35]  J. Oates,et al.  Prostaglandin thromboxane, and 12-hydroxy-5,8,10,14-eicosatetraenoic acid production by ionophore-stimulated rat serosal mast cells. , 1979, Biochimica et biophysica acta.

[36]  D. Desiderio,et al.  Mass spectra of prostaglandins. IV. Trimethylsilyl derivatives of prostaglandins of the F series. , 1973, Analytical biochemistry.